Treatment with L-3,4-dihydroxyphenylalanine (L-Dopa) compensates for decreased striatal dopamine (DA) levels and reduces Parkinson’s disease (PD) symptoms. However, during disease progression, L-Dopa-induced dyskinesia (LID) develops virtually in all PD patients, making the control of PD symptoms difficult. Thus, understanding the mechanisms underlying LID and the control of these motor abnormalities is a major issue in the care of PD patients. From experimental and clinical studies, a complex cascade of molecular and cellular events emerges, but the primary determinants of LID are still unclear. Here, with a translational approach, including four animal models and a wide cohort of PD patients, we show that striatal DA denervation is the major causal factor for the emergence of LID, while α-synuclein aggregates do not seem to play a significant role. Our data also support the concept that maladaptive basal ganglia plasticity is the main pathophysiological mechanism underlying LID.
Servillo, F., De Carluccio, M., Di Lazzaro, G., Campanelli, F., Marino, G., Natale, G., Ledonne, A., Massaro Cenere, M., Paldino, E., Di Giuda, D., Picca, A., Bove, F., Di Iorio, R., Angeloni, B., Cimmino, A. T., Bellomo, G., Picconi, B., Bentivoglio, A. R., Mercuri, N. B., Parnetti, L., Ghiglieri, V., Viscomi, M. T., Calabresi, P., Molecular and cellular determinants of L-Dopa-induced dyskinesia in Parkinson's Disease, <<NPJ PARKINSON'S DISEASE>>, 2024; 10 (1): N/A-N/A. [doi:10.1038/s41531-024-00836-6] [https://hdl.handle.net/10807/302063]
Molecular and cellular determinants of L-Dopa-induced dyskinesia in Parkinson's Disease
Servillo, Federica;De Carluccio, Maria;Di Lazzaro, Giulia;Campanelli, Federica;Di Giuda, Daniela;Bove, Francesco;Di Iorio, Riccardo;Angeloni, Benedetta;Cimmino, Angelo Tiziano;Bentivoglio, Anna Rita;Ghiglieri, Veronica;Viscomi, Maria Teresa;Calabresi, Paolo
2024
Abstract
Treatment with L-3,4-dihydroxyphenylalanine (L-Dopa) compensates for decreased striatal dopamine (DA) levels and reduces Parkinson’s disease (PD) symptoms. However, during disease progression, L-Dopa-induced dyskinesia (LID) develops virtually in all PD patients, making the control of PD symptoms difficult. Thus, understanding the mechanisms underlying LID and the control of these motor abnormalities is a major issue in the care of PD patients. From experimental and clinical studies, a complex cascade of molecular and cellular events emerges, but the primary determinants of LID are still unclear. Here, with a translational approach, including four animal models and a wide cohort of PD patients, we show that striatal DA denervation is the major causal factor for the emergence of LID, while α-synuclein aggregates do not seem to play a significant role. Our data also support the concept that maladaptive basal ganglia plasticity is the main pathophysiological mechanism underlying LID.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
